- Home
- WNEB vs FATE Comparison
WNEB vs FATE Comparison
Compare WNEB & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- FATE
- Stock Information
- Founded
- WNEB 1853
- FATE 2007
- Country
- WNEB United States
- FATE United States
- Employees
- WNEB N/A
- FATE N/A
- Industry
- WNEB Savings Institutions
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WNEB Finance
- FATE Health Care
- Exchange
- WNEB Nasdaq
- FATE Nasdaq
- Market Cap
- WNEB 195.7M
- FATE 129.5M
- IPO Year
- WNEB N/A
- FATE 2013
- Fundamental
- Price
- WNEB $10.73
- FATE $1.14
- Analyst Decision
- WNEB Buy
- FATE Hold
- Analyst Count
- WNEB 3
- FATE 7
- Target Price
- WNEB $11.00
- FATE $3.83
- AVG Volume (30 Days)
- WNEB 85.8K
- FATE 1.4M
- Earning Date
- WNEB 07-22-2025
- FATE 08-12-2025
- Dividend Yield
- WNEB 2.53%
- FATE N/A
- EPS Growth
- WNEB N/A
- FATE N/A
- EPS
- WNEB 0.59
- FATE N/A
- Revenue
- WNEB $76,036,000.00
- FATE $13,335,000.00
- Revenue This Year
- WNEB N/A
- FATE N/A
- Revenue Next Year
- WNEB $7.36
- FATE N/A
- P/E Ratio
- WNEB $18.78
- FATE N/A
- Revenue Growth
- WNEB 2.15
- FATE 105.85
- 52 Week Low
- WNEB $7.38
- FATE $0.66
- 52 Week High
- WNEB $11.68
- FATE $5.75
- Technical
- Relative Strength Index (RSI)
- WNEB 60.17
- FATE 45.71
- Support Level
- WNEB $11.02
- FATE $1.19
- Resistance Level
- WNEB $11.41
- FATE $1.35
- Average True Range (ATR)
- WNEB 0.36
- FATE 0.08
- MACD
- WNEB 0.08
- FATE 0.01
- Stochastic Oscillator
- WNEB 54.98
- FATE 16.00
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.